Clinical Research Directory
Browse clinical research sites, groups, and studies.
Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer
Sponsor: Wenjin Yin
Summary
This is a prospective, randomised, controlled, multicentre study to evaluate the efficacy and safety of continuous versus intermittent pyrotinib therapy in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer.
Official title: Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer: a Prospective, Randomized, Controlled, Multicentre Clinical Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
186
Start Date
2025-08-28
Completion Date
2029-09
Last Updated
2025-11-18
Healthy Volunteers
No
Conditions
Interventions
Pyrotinib
anti-HER2 tyrosine kinase inhibitor
Locations (1)
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Shanghai, China